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Background: Coiled-Coil Domain Containing 88A (CCDC88A) was identified as a substrate of the serine/threonine
kinase Akt that is capable of binding to the actin cytoskeleton. The aim of this study was to investigate the
potential role of CCDC88A in the migration and invasiveness of pancreatic ductal adenocarcinoma (PDAC) cells.
Methods: Immunohistochemistry was performed to determine whether high CCDC88A expression in human PDAC
tissues is correlated with poor prognosis. Immunoprecipitation, immunoblotting and immunocytochemistry were
performed to determine the intracellular distribution of CCDC88A, and its association with the serine/threonine
kinase Akt and actin-filaments in PDAC cells. Phosphoprotein array analysis was performed to determine
CCDC88A-associated intracellular signaling pathways. Finally, immunofluorescence analyses and Matrigel invasion
assays were performed to examine the effects of CCDC88A on the formation of cell protrusions and PDAC cell
invasion.
Results: Expression of CCDC88A in PDAC tissue was significantly correlated with overall survival. CCDC88A was
co-localized with peripheral actin structures in cell protrusions of migrating PDAC cells. Knockdown of CCDC88A
inhibited the migration and invasiveness of PDAC cells through a decrease in cell protrusions. Although CCDC88A
has been previously reported to be a binding partner and substrate of Akt, the level of active Akt was not
associated with the translocation of CCDC88A towards cell protrusions. CCDC88A-dependent promotion of cell
migration and invasiveness was not modulated by Akt signaling. Knockdown of CCDC88A decreased
phosphorylated Src and ERK1/2 and increased phosphorylated AMPK1 in PDAC cells. Knockdown of AMPK1
inhibited the migration and invasiveness of PDAC cells. The combined data suggest that CCDC88A may be a useful
marker for predicting the outcome of patients with PDAC and that CCDC88A can promote PDAC cell migration
and invasion through a signaling pathway that involves phosphorylation of Src and ERK1/2 and/or
dephosphorylation of AMPK1.
Conclusions: CCDC88A was accumulated in cell protrusions, contributed to the formation of membrane
protrusions, and increased the migration and invasiveness of PDAC cells.
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Coiled-Coil Domain Containing 88A (CCDC88A), also
termed Girdin, was identified as a novel substrate of the
serine/threonine kinase Akt (also called protein kinase
B) that is capable of binding to the actin cytoskeleton
[1]. Thus, CCDC88A is a novel component of the phos-
phatidylinositol 3-kinase (PI3-K)⁄Akt signaling pathway,
which is a core-signaling transduction pathway in cancer
[2]. Akt regulates the invasiveness and metastasis of
fibrosarcoma cells in a manner that is highly dependent
on its kinase activity and its membrane-translocating
ability [3]. The COOH terminal domain of CCDC88A
contains its Akt- and actin-binding sites and is also as-
sumed to contribute to the interaction of CCDC88A
with the plasma membrane [4]. Additionally, CCDC88A
can form dimers through the NH2 terminal domain, in-
dicating that it may function as an actin-cross-linking
protein [4]. Upon stimulation of cells with various types
of growth factors, Akt phosphorylates CCDC88A at
Ser-1416 in the COOH terminal domain, which plays an
important role in remodeling of the actin cytoskeleton
during cell migration in fibroblasts [1] and in colorectal
cancer [5]. The phosphorylation of CCDC88A by Akt
occurs at the leading edge, which is required for direc-
tional cell migration and which, in the case of cancer
cells, ultimately leads to invasion and metastasis [6].
Additionally, CCDC88A is phosphorylated by active Akt
following stimulation of breast cancer cells with insulin-
like growth factor (IGF-I), and this phosphorylation
plays an important role in IGF-I-dependent cell move-
ment [7]. Furthermore, CCDC88A-mediated Akt activa-
tion is positively regulated by Gαi, a Gα subunit of
heterotrimeric G proteins that act as intracellular trans-
ducers to mediate signals from G protein-coupled recep-
tors (GPCR) [8, 9]. The guanine nucleotide exchange
motif located in the COOH terminal domain of
CCDC88A activates and sequesters Gαi, thereby enhan-
cing Akt signaling [9]. Thus, CCDC88A serves as a
mediator of the GPCR-Akt signaling pathway.
Pancreatic ductal adenocarcinoma (PDAC) is among
the deadliest of cancers because PDAC cells are highly
invasive and easily invade surrounding tissues, and they
metastasize at an early stage [10]. We recently reported
that an RNA-binding protein, insulin-like growth factor-
2 mRNA-binding protein 3 (IGF2BP3), and IGF2BP3-
bound mRNAs, are accumulated in cell protrusions of
PDAC cells [11]. IGF2BP3-bound mRNAs such as ADP-
ribosylation factor 6 (ARF6) and Rho guanine nucleotide
exchange factor 4 (ARHGEF4) are subsequently trans-
lated in membrane protrusions; in turn, these locally
translated proteins influence the formation of additional
membrane protrusions and thereby increase the motility
and invasiveness of the PDAC cells [11, 12]. IGF2BP3
was also found to bind to CCDC88A mRNA [11]. Thesefindings indicate that local protein expression of
CCDC88A in cell protrusions may modulate the motility
and invasiveness of PDAC cells.
In this study, we analyzed the expression levels of
CCDC88A in human PDAC tissues by using immuno-
histochemistry and evaluated whether high CCDC88A
expression is correlated with poor prognosis. To deter-
mine whether CCDC88A expression might play a crucial
role in the outcome of PDAC through modulation of the
migration and invasiveness of cancer cells, or through its
association with Akt, we next evaluated the role of
CCDC88A in the control of PDAC cell migration and
invasion. In contrast to some previous reports, knock-
down of CCDC88A did not alter the intracellular distri-
bution of Akt in PDAC cells, and CCDC88A promoted
cell migration and invasiveness in an Akt-independent
manner.
Results
CCDC88A expression in human PDAC tissues
We examined CCDC88A expression in surgical specimens
from 102 patients with PDAC by immunohistochemical
analysis. A Histoscore scoring method [13], which takes
into account both the extent of expression and the staining
intensity of CCDC88A, was employed. Expression levels of
CCDC88A were evaluable in all 102 cases, and these cases
were classified into low-expressing (75.5%, n = 77, total im-
munohistochemical score = 2 and 3) and high-expressing
(24.5%, n = 25, total immunohistochemical score = 4, 5 and
6) CCDC88A groups (Table 1). CCDC88A mostly localized
in the cytoplasm of cell bodies (Fig. 1a). Among the high-
expressing CCDC88A group, seven PDAC cases showed
CCDC88A immuno-reactivity that was restricted to the
basolateral portion of the cell in more than 50% of PDAC
tumor cells (Fig. 1b). Weaker staining of CCDC88A in the
basolateral portions of cells in less than 50% of PDAC
tumor cells was seen in all of the low-expressing CCDC88A
PDAC cases (data not shown). Pancreatic ducts were not
obviously stained in normal pancreas, and normal brain,
lung, liver and kidney were not obviously stained with the
CCDC88A antibody (data not shown).
Association between CCDC88A expression,
clinicopathological characteristics and overall survival
We next analyzed the relationship between CCDC88A
expression and clinicopathological features as shown in
Table 2. There was no significant association between
CCDC88A expression and the clinicopathological fea-
tures examined. In addition, there was no significant
correlation between high-expressing CCDC88A PDAC
cases that exhibited CCDC88A expression in the baso-
lateral portions of more than 50% of the PDAC tumor
cells and any of the clinicopathological features (data
not shown).




40–50 3.9 [n = 4]
50–60 16.7 [n = 17]
60–70 31.4 [n = 32]
70–80 40.2 [n = 41]
>80 7.8 [n = 8]
Gender
Male 54.9 [n = 56]
Female 45.1 [n = 46]
Stagea
0 2.0 [n = 2]
IA 4.0 [n = 4]
IB 7.8 [n = 8]
IIA 31.4 [n = 32]
IIB 47.9 [n = 49]
III 2.9 [n = 3]
IV 4.0 [n = 4]
Primary tumora
Tis 2.0 [n = 2]
T1 6.0 [n = 6]
T2 14.5 [n = 15]
T3 75.5 [n = 77]
T4 2.0 [n = 2]
Regional lymph nodesa
N0 46.1 [n = 47]
N1 53.9 [n = 55]
M0 96.1 [n = 98]
M1 3.9 [n = 4]
Histologyb
PanIN 2.0 [n = 2]
well 30.4 [n = 31]
moderate 55.8 [n = 57]
poor 11.8 [n = 12]
Venous invasionb
v0 55.4 [n = 57]
v1 30.7 [n = 31]
v2 10.9 [n = 11]
v3 3.0 [n = 3]
Lymphatic invasionb
ly0 42.6 [n = 43]
ly1 33.6 [n = 34]
ly2 19.9 [n = 21]
ly3 3.9 [n = 4]
Table 1 Summary of characteristics in 102 patients of
pancreatic cancer (Continued)
CCDC88A expression
Low 75.5 [n = 77]
High 24.5 [n = 25]
aClassified according to the classification of International Union against Cancer
bClassified according to the classification of pancreatic cancer of Japan
Pancreas Society; PanIN, pancreatic intraepithelial neoplasia
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with PDAC ranged from 18 to 192 months (median,
64.0 mo). The median survival time was 26 months
(95% confidence interval [CI], 23–33); the 3 year
survival rate was 35.1% (95% CI, 25.6–44.8); and the
5 year survival rate was 25.9% (95% CI, 17.2–35.5).
Kaplan-Meier plots showed that there was a significant
difference in overall survival rates (P = 0.012) between
groups with high and low CCDC88A expression (Fig. 1c,
d). Univariate and multivariate analyses were used to as-
sess the prognostic value of CCDC88A expression in
PDAC. Stage III and IV (the Union for International Can-
cer Control (UICC) TNM classification) (hazard ratio
[HR], 3.035; 95% CI, 1.301–7.081; P = 0.010) and high
CCDC88A expression (HR, 0.497; 95% CI, 0.295–0.836; P
= 0.008) were independent and significant prognostic
factors for worse patient survival by univariate Cox
regression analysis (Table 3). Multivariate survival analysis
indicated that stage III and IV (HR, 11.10; 95% CI, 3.012–
40.92; P < 0.001) and high CCDC88A expression (HR,
0.519; 95% CI, 0.306–0.877; P = 0.014) proved to be inde-
pendent prognostic factors for worse patient survival
(Table 3). The effects of stage III and IV, and CCDC88A
expression on overall survival were similar between uni-
variate and multivariate analyses. Furthermore, the overall
survival rate of the high-expressing CCDC88A group was
compared with that of the low-expressing CCDC88A
group using a receiver operating characteristic (ROC)
curve (Fig. 1e). Such a ROC-curve may be useful for add-
itional application in survival analysis [14]. The area under
the curve (AUC) of the ROC curve was 0.657 (95% CI,
0.536–0.779). The median survival time, 3 year survival
rate and 5 year survival rate of the low-expressing
CCDC88A group were 33 months (95% CI, 24–39), 39.8%
(95% CI, 28.4–51.0) and 31.1% (95% CI, 20.3–42.4),
respectively. The median survival time, 3 year survival rate
and 5 year survival rate of the high-expressing CCDC88A
group were 18 months (95% CI, 14–24), 20.4% (95% CI,
6.8–38.8) and 10.2% (95% CI, 1.8–27.2), respectively.
Subcellular localization of CCDC88A in fibronectin-
stimulated PDAC cells
We performed immunocytochemistry to determine the
subcellular localization of CCDC88A in two types of cul-
tured PDAC cells, moderately differentiated (S2-013 cell
Fig. 1 Association of high expression of CCDC88A with a poor outcome in PDAC patients. a, b. Immunohistochemical staining of PDAC tissues using
anti-CCDC88A antibody. CCDC88A staining was present in the cytoplasm (a) and in the basolateral portions (b) of tumor cells. Arrows, CCDC88A
localized basolaterally. Magnifications: ×200. c, d. Kaplan-Meier analysis of (c) PDAC-specific survival and (d) overall survival according to CCDC88A
expression. e. ROC curve of 102 PDAC cases for analysis of the impact of the total immunohistochemical score of CCDC88A on prognosis
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cells. It has previously been shown that, when S2-013
cells that were initially in suspension attach to an
immobilized fibronectin substrate, nascent membrane
protrusions (de novo formation of actin patches at the
cell periphery) form, and, as these protrusions mature,
they promote cell motility [15, 16]. There were fewer
membrane protrusions formed by S2-013 and Panc-1
cells when the cells were cultured without fibronectin
than when the cells were grown on fibronectin [17].
Our analysis of fibronectin-stimulated S2-013 and
PANC-1 cells indicated that CCDC88A was mainly
present in the cytoplasm of the cell bodies. It should benoted that there was a greater accumulation of
CCDC88A in membrane protrusions that contained
many peripheral actin structures in S2-013 and PANC-
1 cells that were cultured on fibronectin, than in the
corresponding cells cultured without fibronectin
(Fig. 2a). Z stack panels showed that fibronectin-
stimulated S2-013 cells exhibited intracellular expres-
sion of CCDC88A in membrane protrusions (Fig. 2b).
Effects of knockdown of CCDC88A on cell migration and
invasion of PDAC cells
To determine whether CCDC88A participated in the
migration and invasiveness of PDAC cells, CCDC88A




Stagea percentage (%) 0.938
0 2.6 [n = 2] 0 [n = 0]
IA 3.9 [n = 3] 4.0 [n = 1]
IB 7.8 [n = 6] 8.0 [n = 2]
IIA 29.9 [n = 23] 36.0 [n = 9]
IIB 50.6 [n = 39] 44.0 [n = 11]
III 1.3 [n = 1] 4.0 [n = 1]
IV 3.9 [n = 3] 4.0 [n = 1]
Primary tumora 0.656
Tis 2.6 [n = 2] 0 [n = 0]
T1 6.5 [n = 5] 4.0 [n = 1]
T2 13.0 [n = 10] 20.0 [n = 5]
T3 76.6 [n = 59] 72.0 [n = 18]
T4 1.3 [n = 1] 4.0 [n = 1]
Regional lymph nodesa 0.644
N0 44.2 [n = 34] 52.0 [n = 13]
N1 55.8 [n = 43] 48.0 [n = 12]
Distant metastasisa 1
M0 96.1 [n = 74] 96.0 [n = 24]
M1 3.9 [n = 3] 4.0 [n = 1]
Histologyb 0.9391
PanIN 2.6 [n = 2] 0 [n = 0]
Well 29.9 [n = 23] 32.0 [n = 8]
Moderate 54.5 [n = 42] 60.0 [n = 15]
Poor 13.0 [n = 10] 8.0 [n = 2]
Venous invasionb 0.741
v0 + v1 87 [n = 67] 84.0 [n = 21]
V2 + v3 13 [n = 10] 16.0 [n = 4]
Lymphatic invasionb 0.789
ly0 + ly1 76.6 [n = 59] 72.0 [n = 18]
ly2 + ly3 23.4 [n = 18] 28.0 [n = 7]
Recurrence 0.133
Yes 67.5 [n = 52] 84.0 [n = 21]
No 22.5 [n = 25] 16.0 [n = 4]
aClassified according to the classification of International Union against Cancer
bClassified according to the classification of pancreatic cancer of Japan
Pancreas Society; PanIN, pancreatic intraepithelial neoplasia
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CCDC88A-specific small interfering RNA (siRNA) oligos
into S2-013 and PANC-1 cells. Western blot data indi-
cated that, at 48 h after transfection, the expression of
CCDC88A was markedly higher in scrambled control-
siRNA transfected S2-013 and PANC-1 cells than in the
corresponding CCDC88A-siRNA transfected cells (Fig. 3a).Suppression of CCDC88A did not affect cell growth of
S2-013 or PANC-1 cells in an in vitro MTT assay (data
not shown), but it did inhibit cell migration of both cells
in migration assays (Fig. 3b). Furthermore, in two-
chamber invasion assays, CCDC88A-siRNA transfected
cells were significantly less invasive than the control-
siRNA transfected S2-013 and PANC-1 cells (Fig. 3c).
When a CCDC88A-rescue construct was transfected into
CCDC88A-siRNA transfected S2-013 cells, the exogenous
CCDC88A expressed from the rescue construct was local-
ized in the cytoplasm of cell bodies and in cell protrusions,
similar to endogenous CCDC88A (Fig. 3d, e). The trans-
fection of a CCDC88A-rescue construct into CCDC88A-
siRNA transfected S2-013 and PANC-1 cells abrogated
the changes to cell migration and invasiveness caused by
the CCDC88A-siRNA (Fig. 3f, g). These results indicated
that endogenous CCDC88A specifically promotes PDAC
cell migration and invasion.
Co-localization of CCDC88A and actin-filaments in cell
protrusions
To determine if CCDC88A co-localized with actin,
CCDC88A was immunoprecipitated (IP) from lysates of
fibronectin-stimulated S2-013 cells and an anti-actin
antibody was used to detect filamentous actin in multi-
protein complexes that were precipitated by the anti-
CCDC88A antibody. A strong actin band was detected
in immunoblots of the anti-CCDC88A-
immunoprecipitates (Fig. 4a), and actin was enriched in
CCDC88A-IPs compared to control IgG-IPs. Immuno-
fluorescence analysis showed that CCDC88A was associ-
ated with peripheral actin structures in cell protrusions
of fibronectin-stimulated S2-013 cells (Fig. 4b). These
results suggested that CCDC88A is an actin-binding
protein that is present in cell protrusions of PDAC cells.
To determine whether alteration of actin cytoskeleton
dynamics could directly affect the subcellular distribu-
tion of CCDC88A, we treated S2-013 and PANC-1 cells
with the actin depolymerising agent Cytochalasin D.
There were fewer peripheral actin structures in S2-013
and PANC-1 cells exposed to 100 μM Cytochalasin D
for 12 h than in non-treated cells and CCDC88A was
localized in the cytoplasm in the treated cells (Fig. 4c).
Transfection of a CCDC88A-rescue construct into
CCDC88A-siRNA transfected S2-013 and PANC-1 cells
increased peripheral actin structures and co-localization
of the exogenous CCDC88A with peripheral actin
structures in cell protrusions of non-treated cells was
observed; however, such exogenous CCDC88A did not
increase the formation of peripheral actin structures in
Cytochalasin D-treated CCDC88A-siRNA transfected
S2-013 and PANC-1 cells, and exogenous CCDC88A
displayed an intracellular localization in those cells
(Fig. 4d).
Table 3 Univariate and multivariate analysis of prognostic factors for overall survival
Overall survival
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Stagea


















Age 1.025 (0.998–1.053) 0.067 1.024 (0.996–1.052) 0.086
Gender 1.249 (0.771–2.023) 0.366 1.236 (0.759–2.012) 0.393
CCDC88A expression 0.497 (0.295–0.836) 0.008 0.519 (0.306–0.877) 0.014
Diameter of primary tumor 1.338 (1.176–1.524) 1.045e–05
Histologyb 1.383 (0.846–2.261) 0.1965
Lymphatic invasionb
(ly0 + ly1 or ly2 + ly3)
1.269 (0.751–2.145) 0.3733
Venous invasionb
(v0 + v1 or v2 + v3)
1.928 (1.034–3.593) 0.0388
Intrapancreatic nerve invasionb (n0 + n1 or n2 + n3) 1.500 (0.947–2.377) 0.0839
aClassified according to the classification of International Union against Cancer
bClassified according to the classification of pancreatic cancer of Japan Pancreas Society
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To determine whether CCDC88A participated in the
induction of membrane protrusions, we analyzed periph-
eral actin structures in membrane ruffles of fibronectin-
stimulated control scrambled siRNA-transfected S2-013
and PANC-1 and CCDC88A-siRNA transfected S2-013
and PANC-1 cells. Confocal microscopy showed that
CCDC88A-knockdown decreased peripheral actin struc-
tures, compared to control S2-013 and PANC-1 cells
(Fig. 5a, S2-013 cells; Additional file 1: Figure S1a,
PANC-1 cells). Furthermore, CCDC88A-knockdown sig-
nificantly inhibited fibronectin-mediated formation of
membrane protrusions, compared to control S2-013 and
PANC-1 cells (Fig. 5b, S2-013 cells; Additional file 1:
Figure S1b, PANC-1 cells). Transfection of a CCDC88A-
rescue construct into CCDC88A-siRNA transfected
S2-013 and PANC-1 cells abrogated the decrease in
membrane ruffles, which are peripheral actin structures
(Fig. 5c and d, S2-013 cells; Additional file 1: Figure S1c
and d, PANC-1 cells) that was caused by CCDC88A-
siRNA. Since the exogenous CCDC88A from the rescue
construct was strongly accumulated in cell protrusions
and co-localized with actin-filaments in the protrusions
of CCDC88A-siRNA transfected S2-013 and PANC-1
cells (Fig. 5c and e, S2-013 cells; Additional file 1: Figure
S1c and e, PANC-1 cells), CCDC88A that is localized in
cell protrusions could play a role in the formation of
membrane protrusions in PDAC cells.
Roles of CCDC88A in regulation of the activation of Akt
To determine whether CCDC88A was associated with
the regulation of Akt phosphorylation in PDAC cells, weperformed western blot and immunocytochemical ana-
lyses of fibronectin-stimulated scrambled control-siRNA
transfected S2-013 and PANC-1 and CCDC88A-siRNA
transfected S2-013 and PANC-1 cells. Phosphorylated
Akt (Ser-473) in the total cell lysates was unchanged be-
tween cells with scrambled control and cells with knock-
down of CCDC88A (Fig. 6a, S2-013 cells; Additional file
2: Figure S2a, PANC-1 cells). Phosphorylated Akt is
known to be recruited to the plasma membrane by an
increase in PI3K signaling [18]. Immunocytochemical
analysis showed that the subcellular distribution of phos-
phorylated Akt (Ser-473) was not different between
fibronectin-stimulated control-siRNA transfected S2-013
or PANC-1 and CCDC88A-siRNA transfected S2-013 or
PANC-1 cells (Fig. 6b, S2-013 cells; Additional file 2:
Figure S2b, PANC-1 cells). It should be noted that
exogenous CCDC88A was still expressed in the cyto-
plasm of cell bodies, but not at cell protrusions in
CCDC88A-siRNA transfected S2-013 and PANC-1 cells.
Addition of the Akt inhibitor triciribine (5 μM for 2 h)
to the culture medium of S2-013 and PANC-1 cells did
not change the migration or invasiveness of S2-013 and
PANC-1 cells compared with non-treated cells (Fig. 6c,
S2-013 cells; Additional file 2: Figure S2c, PANC-1 cells).
Since MTT analysis showed that triciribine did not
induce growth inhibition of S2-013 and PANC-1 cells at
concentrations of up to 5 μM (data not shown), a
concentration of 5 μM was used to study the effect of
triciribine on cell migration and invasiveness. Further-
more, it has been shown that the binding of IGF-1 to its
receptor triggers the activation of PI3K [19, 20]. We
therefore cultured S2-013 and PANC-1 cells in medium
Fig. 2 Subcellular localization of CCDC88A in PDAC cells. a. Confocal immunofluorescence microscopic images of S2-013 and PANC-1 cells that were
cultured with or without fibronectin and were then labeled with anti-CCDC88A antibody (green) and phalloidin (red; actin filaments). Arrows, CCDC88A
localized in cell protrusions. Blue, nuclear DAPI staining. Bars, 10 μm. b. Confocal Z stack images show nuclear DAPI staining (blue), abundant cytoplasmic
CCDC88A and the accumulation of CCDC88A (green) in membrane protrusions of fibronectin-stimulated S2-013 cells. Arrows, CCDC88A localized in cell
protrusions. The lower and right panels in the confocal Z stack show a vertical cross-section (yellow lines) through the cells. Bar, 10 μm
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ml for 10 min), and the migration and invasion of these
cells were assayed. Although IGF-1 treatment activated
PI3K and Akt, it did not increase the level of phosphory-
lated CCDC88A (Fig. 6d, S2-013 cells; Additional file 2:
Figure S2d, PANC-1 cells). Moreover, IGF-1 treatment
did not change the migration or invasiveness of S2-013
and PANC-1 cells, compared with non-treated cells
(Fig. 6e, S2-013 cells; Additional file 2: Figure S2e,
PANC-1 cells). IGF-1 stimulation did induce the trans-
location of phosphorylated Akt towards the plasma
membranes of S2-013 and PANC-1 cells; however, it did
not change the intracellular distribution of CCDC88A
(Fig. 6f, S2-013 cells; Additional file 2: Figure S2f,
PANC-1 cells). These results suggested that endogenous
CCDC88A was not associated with modulation of the
activity of Akt, and that Akt signaling was not necessary
for the migration or invasion of PDAC cells.Association of CCDC88A and AMPK1 with the formation
of cell protrusions
We further analyzed intracellular signaling pathways
other than the IGF-1-PI3K-Akt pathway in the scram-
bled control-siRNA transfected and CCDC88A-siRNA
transfected S2-013 cells (Fig. 7a). We used a commer-
cially available human phosphoprotein array kit that
allowed semi-quantitative assessment of the levels of
phosphorylated representatives of a number of signaling
pathways including MAP kinase, the Src family, and
JAK/signal transducer and activator of transcription
(STAT) pathways. Consistent with the earlier findings,
phosphorylated Akt was unchanged between scrambled
control-siRNA transfected S2-013 cells and CCDC88A-
siRNA transfected S2-013 cells. Of the 38 kinases inves-
tigated, suppression of CCDC88A resulted in the
inactivation of Src and extracellular signal-regulated
kinase (ERK) 1/2, and the activation of adenosine
Fig. 3 Roles of CCDC88A in cell migration and invasion. a. Western blotting of CCDC88A following transient transfection of S2-013 and PANC-1 cells
with a single mixture containing four different siRNA oligonucleotides targeting CCDC88A (siCCDC88A) or negative scrambled control (Scr). Western
blotting was performed using an anti-CCDC88A antibody. b, c. Oligonucleotides targeting CCDC88A or Scr were transiently transfected into S2-013 and
PANC-1 cells. Migration (b) and two-chamber invasion assays (c) were performed. Migrating cells in four fields per group were scored. Data are derived
from three independent experiments. Columns, mean; bars, SD. *p < 0.005 compared with Scr-transfected control (Student’s t-test). d, e. Western blots
(d) and confocal immunofluorescence microscopic images (e). Mock control vector or a myc-tagged CCDC88A-rescue construct was transiently
transfected into scrambled control-siRNA and CCDC88A-siRNA transfected S2-013 and PANC-1 cells; after 48 h, the cells were incubated on fibronectin
for 5 h. Western blots probed with anti-myc and anti-CCDC88A antibodies are shown. Cells were stained with anti-myc antibody (green). Actin fila-
ments were labeled with phalloidin (red). Arrows, myc-tagged CCDC88A localized in cell protrusions. Blue, DAPI staining. Bar, 10 μm. f, g. Mock control
vector or a myc-tagged CCDC88A-rescue construct was transiently transfected into scrambled control-siRNA and CCDC88A-siRNA transfected S2-013
and PANC-1 cells; 48 h later, migration (f) and two-chamber invasion assays (g) were performed. Migrating cells in four fields per group were counted.
Data are derived from three independent experiments. Columns, mean; bars, SD. *p < 0.005 compared with corresponding CCDC88A-siRNA transfected
S2-013 cells that were transfected with mock vector (Student’s t-test)
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Immunofluorescent analysis of fibronectin-stimulated
S2-013 and PANC-1 cells indicated that, in addition to
CCDC88A, AMPK1 also accumulated in cell protrusions(Fig. 7b, S2-013 cells; Additional file 3: Figure S3,
PANC-1 cells).
The high expression of AMPK1 in S2-013 and PANC-
1 cells was transiently suppressed by AMPK1-specific
Fig. 4 Co-localization of CCDC88A with actin-filaments in cell protrusions. a. Immunoprecipitation (IP) of CCDC88A from S2-013 cells cultured on
fibronectin. Proteins within the immunoprecipitates were examined by western blotting. The blots were probed with antibodies against CCDC88A and
actin. Mouse IgG isotype control antibody was used as an isotype control. b. Confocal immunofluorescence microscopic images show nuclear DAPI
staining (blue), abundant cytoplasmic CCDC88A, and the accumulation of CCDC88A (green) in membrane protrusions of fibronectin-stimulated S2-013
cells. Actin filaments were labeled with phalloidin (red). Arrows, CCDC88A that was colocalized with actin-filaments in cell protrusions. Bar, 10 μm. c.
Confocal immunofluorescence microscopic images of S2-013 and PANC-1 cells that were pretreated with 100 μM Cytochalasin D for 12 h and were
then incubated on fibronectin. Cells were stained with anti-CCDC88A antibody (green). Actin filaments were labeled with phalloidin (red). Arrows,
CCDC88A that was colocalized with actin-filaments in cell protrusions. Blue, DAPI staining. Bars, 10 μm. d. Confocal immunofluorescence microscopic
images. CCDC88A-siRNA transfected S2-013 and PANC-1 cells, which were transiently transfected with a myc-tagged CCDC88A-rescue construct, were
pretreated with 100 μM Cytochalasin D for 12 h, and were subsequently incubated on fibronectin. Cells were stained with anti-myc antibody (green).
Actin filaments were labeled with phalloidin (red). Arrows, CCDC88A that was colocalized with actin-filaments in cell protrusions. Blue, DAPI staining.
Bars, 10 μm
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Fig. 5 Roles of CCDC88A in the formation of cell protrusions. a. Confocal Z stack images of S2-013 cells that were transiently transfected with
scrambled control-siRNA (Scr) or CCDC88A-siRNA (siCCDC88A). The transfected cells were incubated on fibronectin, and were subsequently stained
with anti-CCDC88A antibody (green) and phalloidin (red). The lower and right panels in the confocal Z stack show a vertical cross-section (yellow lines)
through the cells. Arrows, peripheral actin structures in cell protrusions of control-siRNA transfected cells. Blue, nuclear DAPI staining. Bars, 10 μm. b.
Quantification of the data shown in Fig. 5a. Columns, mean; bars, SD. *p < 0.001 compared with Scr-transfected controls (Student’s t-test). c. Confocal
immunofluorescence microscopic images of S2-013 cells that had been transfected with CCDC88A-siRNA and were subsequently transfected with a
myc-tagged CCDC88A-rescue construct. After 48 h, the cells were incubated on fibronectin. Cells were stained with anti-myc antibody (green),
anti-CCDC88A antibody (red) and phalloidin (violet). Arrows, cell protrusions reproduced by myc-tagged CCDC88A in CCDC88A-siRNA transfected cells.
Blue, DAPI staining. Bars, 10 μm. d. Quantification of the data shown in Fig. 5c; the values represent the number of cells with fibronectin-mediated cell
protrusions in which peripheral actin structures were increased. All cells in four fields per group were scored. Data are derived from three independent
experiments. Columns, mean; bars, SD. *p < 0.001 compared with corresponding CCDC88A-siRNA transfected S2-013 cells that were transfected with
mock vector (Student’s t-test) e. Confocal Z stack images showing nuclear DAPI staining (blue) and the accumulation of myc-tagged CCDC88A (green)
in fibronectin-stimulated CCDC88A-siRNA transfected S2-013 cells transfected with the myc-tagged CCDC88A-rescue construct. Arrows, myc-tagged
CCDC88A accumulated in cell protrusions. The lower and right panels of the confocal Z stack show a vertical cross-section (yellow lines) through the
cells. Bar, 10 μm
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that, 48 h after transfection, the expression of AMPK1
was much higher in scrambled control siRNA trans-
fected S2-013 and PANC-1 cells than in thecorresponding AMPK1-siRNA transfected cells. Interest-
ingly, transfection of a CCDC88A-rescue construct into
S2-013 and PANC-1 cells in which both endogenous
CCDC88A and AMPK1 had been suppressed did not
Fig. 6 Roles of CCDC88A in regulating the activation of Akt. a. Scr or siCCDC88A oligos were transfected into S2-013 cells. After 48 h, the cells were
incubated on fibronectin for 5 h, and whole cell lysates were prepared for western blot analysis using anti-CCDC88A, anti-Akt and anti-phosphorylated
Akt antibodies. Data are representative of three independent experiments. b. Confocal immunofluorescence microscopic images of S2-013 cells that
were transiently transfected with scrambled control-siRNA or CCDC88A-siRNA. After 48 h, the cells were incubated on fibronectin for 5 h and were then
stained with anti-phosphorylated Akt antibody (green), anti-CCDC88A antibody (red) and phalloidin (violet; actin filaments). Blue, nuclear DAPI staining.
Bars, 10 μm. c. S2-013 cells were pretreated with or without 5 μM of the Akt inhibitor triciribine for 2 h, following which the cells were plated on
migration (left panel) and Matrigel invasion (right panel) chambers. Migrated cells in four fields per group were counted. Data are representative of
three independent experiments. Columns, mean; bars, SD. d. S2-013 cells were pretreated with or without 100 ng/mL IGF-1 for 10 min, and whole
cell lysates were prepared for western blot analysis using anti-CCDC88A, anti-phosphorylated CCDC88A, anti-PI3K, anti-phosphorylated PI3K, anti-Akt,
and anti-phosphorylated Akt antibodies. Data are representative of three independent experiments. e. S2-013 cells were pretreated with or without
100 ng/mL IGF-1 for 10 min and the cells were then plated on migration (left panel) and Matrigel invasion (right panel) chambers. Migrated cells in four
fields per group were counted. Data are representative of three independent experiments. Columns, mean; bars, SD. f. Confocal immunofluorescence
microscopic images of S2-013 cells that were cultured on fibronectin with or without IGF-1 stimulation following which the cells were stained with
anti-phosphorylated Akt antibody (green), anti-CCDC88A antibody (red) and phalloidin (violet; actin). Arrows, phosphorylated Akt accumulated in cell
protrusions; arrowheads, CCDC88A accumulated in cell protrusions. Blue, nuclear DAPI staining. Bars, 10 μm
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filaments were assembled (Fig. 7d). Moreover, transfec-
tion of a CCDC88A-rescue construct into S2-013 and
PANC-1 cells in which both endogenous CCDC88A and
AMPK1 had been suppressed did not induce the accu-
mulation of exogenous CCDC88A at peripheral actin
structures (Fig. 7d).Association of CCDC88A and AMPK1 with the cell
migration and invasion of PDAC cells
Trans-well migration and Matrigel invasion assays, and
siRNA-mediated knockdown were used to examine the
effect of AMPK1 on the migration and invasiveness of
S2-013 and PANC-1 cells. In the trans-well migration
assays, the migration of both S2-013 and PANC-1 cells
Fig. 7 Association of CCDC88A and AMPK1 with cell migration and invasion. a. Effects of suppression of CCDC88A on the expression of selected
phosphoproteins in S2-013 cells. Cell extracts obtained from fibronectin-stimulated scrambled control-siRNA transfected S2-013 cells or CCDC88A-siRNA
transfected S2-013 cells were probed on human phosphoprotein arrays. b. Confocal immunofluorescence microscopic images of S2-013 cells that were
cultured on fibronectin and were then labeled with anti-AMPK1 antibody (green), anti-CCDC88A antibody (red) and phalloidin (violet; actin filaments).
Arrows, AMPK1 localized in cell protrusions. Blue, nuclear DAPI staining. Bar, 10 μm. c. Western blot analysis of AMPK1 following transient transfection of
S2-013 and PANC-1 cells with a single mixture containing four different siRNA oligonucleotides targeting AMPK1 (siAMPK1) or negative scrambled
control (Scr). Western blotting was performed using an anti-AMPK1 antibody. d. Confocal immunofluorescence microscopic images. A myc-tagged
CCDC88A-rescue construct was transfected into S2-013 and PANC-1 cells that had been transfected with both CCDC88A-siRNA and AMPK1-siRNA. 48 h
later, the cells were incubated on fibronectin. Cells were stained with anti-myc antibody (violet), anti-AMPK1 antibody (green), and phalloidin (red). Blue,
DAPI staining. Bars, 10 μm. e. siRNA oligonucleotides targeting AMPK1 or Scr were transiently transfected into S2-013 and PANC-1 cells. After 48 h,
migration and two-chamber invasion assays were performed. Migrating cells in four fields per group were scored (lower panel). Data are representative
of three independent experiments. Columns, mean; bars, SD. *p < 0.008 compared with Scr-transfected control (Student’s t-test). f, g. A myc-tagged
CCDC88A-rescue construct was transfected into S2-013 (f) and PANC-1 (g) cells that had been transfected with CCDC88A-siRNA and AMPK1-siRNA; 48 h
later, migration and two-chamber invasion assays were performed. Migrating cells in four fields per group were counted. Data are derived from three
independent experiments. Columns, mean; bars, SD. *p < 0.005 compared with corresponding CCDC88A-siRNA and AMPK1-siRNA transfected cells that
were transfected with mock vector (Student’s t-test)
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in control cells (Fig. 7e). In two-chamber invasion
assays, the invasiveness of S2-013 and PANC-1 cells was
significantly lower in AMPK1-knockdown cells than in
control cells (Fig. 7e). Moreover, transfection of a
CCDC88A-rescue construct into S2-013 and PANC-1
cells in which both endogenous CCDC88A and AMPK1
expression had been suppressed did not abrogate the
changes to cell migration and invasiveness caused by the
CCDC88A-siRNA and AMPK1-siRNA (Fig. 7f, S2-013
cells; Fig. 7g, PANC-1 cells). These results indicated that
AMPK1 was necessary for the CCDC88A-associated
promotion of migration and invasiveness of PDAC cells.
Discussion
In this study, we showed that CCDC88A is a significant
prognostic factor whose expression levels predict the
overall survival of patients with PDAC. Individual clini-
copathological factors were not significantly correlated
with CCDC88A expression, which may be due to the re-
markably short overall survival of patients with PDACs
(Table 2). The important fact that patients with high
CCDC88A expression showed significantly worse overall
survival in both univariate and multivariate analyses sug-
gested that high CCDC88A expression might be a novel
and independent prognostic factor of PDAC (Table 3).
Immunocytochemical analysis of the present study indi-
cated that CCDC88A accumulated in cell protrusions of
PDAC cells. Immunohistochemical analysis additionally
showed that CCDC88A was more abundantly localized
in the basolateral portions of PDAC cells in the high-
expressing CCDC88A group, compared to the low-
expressing CCDC88A group (Fig. 1b). PDAC is one of
the deadliest of cancers due to its ability to extensively
invade surrounding tissues and to metastasize at an early
stage [10]. Extensive local infiltration and metastasis are
the main causes of death in PDAC [21]. Since the forma-
tion of cell protrusions is essential for cell migration and
invasion, we investigated the role of CCDC88A in the
promotion of migration and invasiveness of PDAC cells
through the formation of cell protrusions. Moreover, we
confirmed that CCDC88A was clearly not expressed in
normal organs such as pancreas, brain, lung, liver, and
kidney. Consequently, CCDC88A is an essential marker
of poor prognosis that is functionally related to cell mi-
gration and invasion through promotion of an increase
in the formation of cell protrusions.
CCd for enhancement of the activity of Akt, the remod-
eling of actin, and the triggering of cell migration by
growth factors such as epidermal growth factor (EGF),
IGF, vascular endothelial growth factor (VEGF) and insu-
lin [1, 5, 9]. The reported mechanism by which the EGF
receptor enhances the activity of Akt via CCDC88A is that
the carboxy terminus of CCDC88A directly binds theautophosphorylated cytoplasmic tail of the EGF receptor
and thereby links G-protein to ligand-activated receptors
[21]. The carboxy terminus of CCDC88A also serves as a
common platform that links ligand-activated receptors at
the leading edge to actin, Akt, and Gαi, 3 whose interplay
is essential for cell migration [1, 5, 9, 22]. Furthermore, in
response to migratory cues such as growth factors, phos-
phorylation of CCDC88A by Akt occurs at the leading
edge and this phosphorylation is required for directional
cell migration that, in the case of cancer cells, ultimately
leads to cell invasion and metastasis [7]. Thus, CCDC88A
functions as a signal transducer in the PI3-K/Akt signaling
pathway, and plays important roles in Akt-dependent cell
invasion and metastasis. We showed that IGF-1 stimula-
tion that induced the translocation of phosphorylated Akt
towards the plasma membrane did not increase the level
of phosphorylated CCDC88A (Fig. 6d) or alter the intra-
cellular distribution of CCDC88A in PDAC cells (Fig. 6f).
We suggest that CCDC88A assembled in cell protrusions
in PDAC cells, where it co-localized with actin-filaments,
but that the level of active Akt was not associated with the
translocation of CCDC88A towards cell protrusions
(Fig. 6b). Additionally, treatment of fibronectin-stimulated
PDAC cells with the Akt inhibitor triciribine did not
change the formation of cell protrusions (data not shown)
or cell migration or invasiveness (Fig. 6c, Additional file 2:
Figure S2c). Our in vitro assays showed that neither the
phosphorylation level of CCDC88A nor CCDC88A-
dependent cell invasion were associated with the
phosphorylation level of Akt in PDAC cells. Our results
therefore suggested that CCDC88A functioned in the pro-
motion of cell migration and invasion without association
with Akt-signaling pathways in PDAC cells.
We showed that knockdown of CCDC88A decreased
peripheral rearrangements of the actin cytoskeleton in
PDAC cells cultured on fibronectin, and that exogenously
overexpressed CCDC88A significantly increased periph-
eral actin-cytoskeletal rearrangements in CCDC88A-
siRNA transfected PDAC cells. CCDC88A localizes to the
actin cytoskeleton including to stress fibers (actin
microfilament bundles) and cortical actin filaments where
it can bind to both the plasma membrane and actin fila-
ments [1]. Consistent with the results of a previous report
[1], treatment with Cytochalasin D decreased the
co-localization of CCDC88A with actin filaments in cell
protrusions of PDAC cells (Fig. 4c). Moreover, transfection
of a CCDC88A-rescue construct into PDAC cells in which
endogenous CCDC88A expression was suppressed failed
to increase peripheral actin-cytoskeletal rearrangements in
Cytochalasin D treated cells (Fig. 4d). The fact that
CCDC88A remained in the cytoplasm of cell bodies of
CCDC88A-siRNA transfected PDAC cells (Fig. 5a and
6b), suggested that it is the CCDC88A that accumulates at
the cell membranes that contributes to peripheral actin-
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processes at the leading edge of migrating cells are
complex and involve increased actin filament severing,
capping and dendritic branching [23]. Migratory compe-
tence of tumor cells requires activation of the motile cycle,
the first step of which is actin remodeling, which drives
the formation of cell protrusions, defines the direction of
migration and initiates the growth of the lamellipodia
[24]. Given that CCDC88A played a role in regulating per-
ipheral actin-rearrangements, the observation that
CCDC88A co-localized with actin-filaments in cell protru-
sions indicated that CCDC88A must contribute to the
regulation of membrane ruffles, resulting in the promo-
tion of PDAC cell migration and invasion. The mechan-
ism by which CCDC88A promotes cell migration and
invasion thorough the regulation of membrane protru-
sions in PDAC cells is still unknown. We found that
CCDC88A knockdown inactivated Src and ERK1/2 in
S2-013 cells (Fig. 7a). Src is at the cross-roads of several
signaling pathways, including Ras/Raf/ERK1/2, PI3K/Akt,
and STAT 3 pathways [24–26], resulting in the regulation
of cell proliferation, survival, invasion, migration and
angiogenesis. Furthermore, CCDC88A knockdown acti-
vated the highly conserved, energy-sensing serine/threo-
nine kinase AMPK1 (Fig. 7a). Interestingly, AMPK1 also
accumulated in cell protrusions of fibronectin-stimulated
PDAC cells (Fig. 7b). Knockdown of AMPK1 inhibited
PDAC cell migration and invasion (Fig. 7e). Transfection
of a CCDC88A-rescue construct into PDAC cells in which
both CCDC88A and AMPK1 were suppressed failed to
increase the formation of cell protrusions, or cell migra-
tion and invasion (Fig. 7d, f and g). These findings
suggested that AMPK1 pathways might be associated with
CCDC88A-dependent migration and invasiveness.
Although many studies support a tumor-suppressive role
of AMPK [27, 28], emerging evidence suggests that this
function of AMPK1 might be overridden by stress or
oncogenic signals so that, under such conditions, tumor
cells use AMPK activation as a survival strategy to gain
growth advantage [29]. Future studies should evaluate the
detailed CCDC88A-associated signaling cascades that
coordinate the actin-cytoskeletal remodeling that is re-
quired for cell spreading and cell migration and invasion.
Conclusions
The findings presented in this study are supportive of
the pivotal roles of CCDC88A in the coordinated regula-
tion of cortical actin changes. The functional significance
of CCDC88A, which mediates migration and invasive-
ness without association with Akt signaling in PDAC
cells, was established. The data presented here indicated
that inhibition of CCDC88A may be effective for tar-
geted molecular therapy, because any such therapy
would limit the migration and invasiveness of PDACs.Methods
Primary human PDAC samples
Patients (n = 102) who underwent surgical treatment for
PDAC at the Departments of Surgery, Kochi Medical
School Hospital (Nankoku, Japan) and Matsuyama
Shimin Hospital (Matsuyama, Japan) between 1999 and
2014 were studied (clinicopathological findings of these
102 patients are summarized in Table 1. The follow-up
period for survivors ranged from 18 to 192 months (mo)
(median, 64.0 mo). Of these patients, 83 had received
adjuvant chemotherapy with gemcitabine or S-1, or che-
moradiation therapy after resection of the PDAC.
Tumors were classified according to the classification of
pancreatic carcinoma of the Japan Pancreas Society [30]
and the UICC TNM classification [31].
Antibodies
Anti-CCDC88A antibody (MABT100) and the JLA20
anti-actin antibody (MABT219) were purchased from
Merck Millipore (Temecula, CA). Anti-phosphorylated
CCDC88A (Ser1416) antibody (28067) was purchased
from Immuno-Biological Laboratories (Gunma, Japan).
Anti-phosphorylated PI3K (Tyr458/Tyr199) (4228), anti-
PI3K (pan) (4257), anti-phosphorylated Akt (Ser473)
(9271), and anti-Akt (pan) (4691) antibodies were
purchased from Cell Signaling (Grand Island, NY). Anti-
AMPK1 antibody (A300-507A) was purchased from
Bethyl Laboratories (Montgomery, TX). Anti-myc (A14)
antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA).
Immunohistochemical staining
Tissue sections from normal pancreas, brain, lung, liver
and kidney were purchased from Biochain (Hayward,
CA). The sections were deparaffinized and autoclaved at
108 °C for 15 min. After endogenous peroxidase activity
was quenched by incubation for 30 min in 0.33% hydro-
gen peroxide diluted in methanol, the sections were
blocked by incubation with fetal bovine serum. Sections
were then incubated with anti-CCDC88A antibody at
room temperature for 1 h and were subsequently
washed with PBS. Immunodetection was performed with
peroxidase-labeled anti-rabbit immunoglobulin (Dako
Cytomation, Carpinteria, CA). Finally, the reactants were
developed with 3,3′-diaminobenzidine (Dako), and the
sections were counterstained with hematoxylin.
Evaluation of CCDC88A staining
CCDC88A staining was evaluated by two independent ob-
servers (SN and MF) who were blinded to clinical and out-
come data. Immunoreactivity was scored semiquantitatively
according to the estimated percentage of positive tumor
cells (1, <50%; 2, 50-80%; 3, >80% reactive cells) and inten-
sity (1, weaker; 2, equal to; and 3, stronger than the staining
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of Langerhans was not significantly stained, were consid-
ered to be in bad condition and were not evaluated. A total
immunohistochemical score was calculated by summing
the percentage score and the intensity score. The quantity
of CCDC88A expression was classified into two groups
based on the total score (low group, 2–3; high group, 4–6)
with reference to a previous report [13].
Cell culture
The human PDAC cell line S2-013, a subline of SUIT-2,
was obtained from Dr. T. Iwamura (Miyazaki Medical
College, Miyazaki, Japan) [32]. The human PDAC cell
line PANC-1 was purchased from the American Type
Culture Collection (Manassas, VA). All cells were grown
in Dulbecco’s modified Eagle’s medium (DMEM; Gibco-
BRL, Carlsbad, CA) supplemented with 10% heat-
inactivated fetal calf serum (FCS) at 37 °C in a humidi-
fied atmosphere saturated with 5% CO2. In selected ex-
periments, cell suspensions were cultured with IGF-1
(100 ng/mL; Sigma-Aldrich, St. Louis, MO) for 10 min
and the Akt inhibitor triciribine (5 μM; Sigma-Aldrich)
for 2 h.
Confocal immunofluorescence microscopy
Coverslips were coated with 10 μg/mL fibronectin
(Sigma-Aldrich) for 1 h at room temperature. Cells were
seeded on fibronectin-coated glass coverslips and incu-
bated for 5 h. The cells were then fixed with 4% parafor-
maldehyde, permeabilized with 0.1% Triton X-100,
covered with blocking solution (3% BSA/PBS), and then
incubated with the primary antibody for 1 h. Alexa488-
or Alexa594-conjugated secondary antibody (Molecular
Probes, Carlsbad, CA) was then applied with or without
Alexa647-conjugated phalloidin (Cytoskeleton, Denver,
CO). In some experiments, a commercial antibody-
labeling technology (Zenon; Life Technologies, Carlsbad,
CA) was used according to the manufacturer’s instruc-
tions to conjugate green or red fluorophores to primary
antibodies. Each specimen was visualized using a Zeiss
LSM 510 META microscope (Carl Zeiss, Gottingen,
Germany).
siRNA treatment
A single mixture with four different siRNA oligonucleo-
tides (oligos) targeting CCDC88A or AMPK1 was
purchased from Qiagen (FlexiTube GeneSolution siRNA
GS55704 and GS5562, respectively; Valencia, CA) and a
single mixture with four different scrambled negative
control siRNA oligos was obtained from Santa Cruz
(37007). To examine the effect of the siRNAs on
CCDC88A expression, S2-013 and PANC-1 cells that
expressed CCDC88A were plated in six-well plates. After
20 h, the cells were transfected with 80 pmol of eachsiRNA mixture in siRNA transfection reagent (Qiagen)
following the manufacturer’s instructions. After incuba-
tion for 48 h, the cells were processed for western
blotting or for transwell migration or Matrigel invasion
assays.CCDC88A-rescue construct
Reverse transcription-PCR (RT-PCR) was used to amplify
the entire coding sequence of the CCDC88A cDNA. The
resultant PCR product was subsequently inserted into a
separate pCMV6-Entry vector (Origene Technologies,
Rockville, MD) bearing a C-terminal myc-DDK-tag. The
X-tremeGENE HP DNA Transfection Reagent (Roche,
Penzberg, Germany) was used to transiently transfect tar-
get cells with the resultant CCDC88A-rescue construct.Immunoprecipitation
S2-013 cells were seeded onto fibronectin and incubated
for 5 h. The cells were then lysed in lysis buffer (20 mM
HEPES (pH 7.4), 100 mM KCl, 5 mM MgCl2, 0.5% Triton
X-100, protease inhibitor cocktail tablets (Roche) and a
phosphatase inhibitor cocktail (Nacalai, Kyoto, Japan)).
Lysates were immunoprecipitated with Dynabeads Protein
G (Dynal, Oslo, Norway) and with anti-CCDC88A
antibody or mouse IgG isotype control antibody for 2 h at
4 °C. Beads were pelleted using a magnetic rack (Dynal)
and were subsequently analyzed using western blotting.Immunoblot analysis of cell lysates
Each cell pellet was resuspended in a buffer containing
20 mM Hepes (pH 7.4), 100 mM KCl, 2 Mm MgCl2,
0.5% Triton X-100, protease inhibitor cocktail tablets
(Roche) and a phosphatase inhibitor cocktail (Nacalai,
Kyoto, Japan). The bicinchoninic acid (BCA) assay was
used to determine protein concentration in each lysate;
an aliquot of each lysate was then diluted with sample
buffer (50 mM Tris, 2% SDS, 0.1% bromophenol blue
and 10% glycerol) to a final concentration of 1–2 μg/μL
and was analyzed by SDS-PAGE and western blotting.Trans-well migration assay
Cells (3.0 × 104) were plated in the upper chamber of BD
BioCoat Control Culture Inserts (24-well plates, 8-μm
pore size; Becton Dickinson, San Jose, CA). Serum-free
culture medium was added to each upper chamber, and
medium containing 5% FCS was added to the bottom
chamber. Cells were incubated on the membranes for
12 h. After this 12-h incubation, four independent visual
fields were examined via microscopic observation to
count the number of cells that had moved to the bottom
chamber.
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A two-chamber invasion assay was used to assess cell
invasion (24-well plates, 8-μm pore size membrane
coated with a layer of Matrigel extracellular matrix pro-
teins; Becton Dickinson). Cells (4.0 × 104) suspended in
serum-free medium were seeded into the upper chamber
and allowed to invade towards a 5% FCS chemoattract-
ant in the lower chamber. After a 20-h incubation, four
independent visual fields were examined via microscopic
observation to count the number of cells that had
moved to the bottom chamber.
Determination of patterns of protein phosphorylation
Relative protein phosphorylation levels of 38 selected
proteins in scrambled control-siRNA transfected S2-013
cells and CCDC88A-siRNA transfected S2-013 cells were
obtained by profiling 46 specific phosphorylation sites
using the Proteome Profiler Human Phospho-Kinase
Array Kit ARY003 from R&D Systems (Minneapolis,
MN), according to the manufacturer’s instructions.
Briefly, cells were rinsed with PBS, and 1 × 107 cells/ml
lysis buffer were solubilized with permanent shaking at
4 °C for 30 min. Aliquots of the lysates were stored fro-
zen at −80 °C. Membranes with spotted catcher anti-
bodies were incubated with diluted cell lysates at 4 °C
overnight. Thereafter, cocktails of biotinylated detection
antibodies were added at room temperature for 2 h.
Phosphorylated proteins were detected using a horserad-
ish peroxidase conjugated anti-mouse/rabbit antibody.
Blots were then incubated with an enhanced chemilu-
minescence solution for 1 min for signal detection.
Statistical analysis
The StatFlex software (Ver6; YUMIT, Osaka, Japan) and
SAS software (Ver9.1.3; SAS Institute, Cary, NC) were used
for statistical analysis. Student’s t-test was used for the com-
parison of continuous variables. Fisher’s exact test was used
to assess the association between CCDC88A expression
levels and clinicopathological parameters. The following pa-
rameters were examined: age, sex and the TNM classifica-
tion or pathological stage using the Japan Pancreas Society
[30] and the International Union against Cancer [31] score
systems. Overall survival time was measured from the date
of surgery to the date of death due to any cause or last
clinical follow-up as determined by review of electronic
medical records. Survival curves were plotted using the
Kaplan-Meier method and were compared using the log-
rank test (Mantel-Cox). Survival rates are given as median
values and interquartile ranges (IQRs). ROC curves [14]
were generated and analyzed using StatFlex software. Inde-
pendent factors for overall survival including age, sex and
pathological stage were assessed using Cox proportional
hazards regression analysis. The relative hazard for each
patient was calculated from coefficients determined byCox regression. P values of < 0.05 were considered to be
statistically significant. All tests were two-tailed.Additional files
Additional file 1: Figure S1. Roles of CCDC88A in the formation of cell
protrusions in PANC-1 cells. a. Confocal Z stack images of PANC-1 cells that
were transiently transfected with scrambled control-siRNA (Scr) or
CCDC88A-siRNA (siCCDC88A). The transfected cells were incubated on
fibronectin, and were subsequently stained with anti-CCDC88A antibody
(green) and phalloidin (red). The lower and right panels in the confocal Z
stack show a vertical cross-section (yellow lines) through the cells. Arrows,
peripheral actin structures in cell protrusions of control-siRNA transfected
cells. Blue, nuclear DAPI staining. Bars, 10 μm. b. Quantification of the data
shown in Figure S1a. Columns, mean; bars, SD. *p < 0.001 compared with
Scr-transfected controls (Student’s t-test). c. Confocal immunofluorescence
microscopic images of PANC-1 cells that had been transfected with
CCDC88A-siRNA and were subsequently transfected with a myc-tagged
CCDC88A-rescue construct. After 48 h, the cells were incubated on
fibronectin. Cells were stained with anti-myc antibody (green), anti-CCDC88A
antibody (red) and phalloidin (violet). Arrows, cell protrusions reproduced by
myc-tagged CCDC88A in CCDC88A-siRNA transfected cells. Bars, 10 μm. d.
Quantification of the data shown in Figure S1c; the values represent the
number of cells with fibronectin-mediated cell protrusions in which peripheral
actin structures were increased. All cells in four fields per group were scored.
Data are derived from three independent experiments. Columns, mean; bars,
SD. *p < 0.001 compared with corresponding CCDC88A-siRNA transfected
PANC-1 cells that were transfected with mock vector (Student’s t-test). e.
Confocal Z stack images showing nuclear DAPI staining (blue) and the
accumulation of myc-tagged CCDC88A (green) in fibronectin-stimulated
CCDC88A-siRNA transfected PANC-1 cells transfected with the myc-tagged
CCDC88A-rescue construct. Arrows, myc-tagged CCDC88A accumulated in cell
protrusions. The lower and right panels of the confocal Z stack show a vertical
cross-section (yellow lines) through the cells. Bar, 10 μm. (DOCX 1733 kb)
Additional file 2: Figure S2. Roles of CCDC88A in regulating the
activation of Akt in PANC-1 cells. a. Scr or siCCDC88A oligos were
transfected into PANC-1 cells. After 48 h, the cells were incubated on
fibronectin for 5 h, and whole cell lysates were prepared for western blot
analysis using anti-CCDC88A, anti-Akt and anti-phosphorylated Akt
antibodies. b. Confocal immunofluorescence microscopic images of
PANC-1 cells that were transiently transfected with scrambled control-
siRNA or CCDC88A-siRNA. After 48 h, the cells were incubated on
fibronectin for 5 h and were then stained with anti-phosphorylated Akt
antibody (green), anti-CCDC88A antibody (red) and phalloidin (violet;
actin filaments). Blue, nuclear DAPI staining. Bars, 10 μm. c. PANC-1 cells
were pretreated with or without 5 μM of the Akt inhibitor triciribine for
2 h, following which the cells were plated on migration (left panel) and
Matrigel invasion (right panel) chambers. Migrated cells in four fields per
group were counted. Data are representative of three independent
experiments. Columns, mean; bars, SD. d. PANC-1 cells were pretreated
with or without 100 ng/mL IGF-1 for 10 min, and whole cell lysates
were prepared for western blot analysis using anti-CCDC88A,
anti-phosphorylated CCDC88A, anti-PI3K, anti-phosphorylated PI3K,
anti-Akt, and anti-phosphorylated Akt antibodies. e. PANC-1 cells were
pretreated with or without 100 ng/mL IGF-1 for 10 min and the cells
were then plated on migration (left panel) and Matrigel invasion (right
panel) chambers. Migrated cells in four fields per group were counted.
Data are representative of three independent experiments. Columns,
mean; bars, SD. f. Confocal immunofluorescence microscopic images of
PANC-1 cells that were cultured on fibronectin with or without IGF-1
stimulation following which the cells were stained with anti-phosphorylated
Akt antibody (green), anti-CCDC88A antibody (red) and phalloidin (violet;
actin). Arrows, phosphorylated Akt accumulated in cell protrusions;
arrowheads, CCDC88A accumulated in cell protrusions. Bars, 10 μm.
(DOCX 1979 kb)
Additional file 3: Figure S3. Subcellular localization of CCDC88A and
AMPK1 in PANC-1 cells. Confocal immunofluorescence microscopic
images of PANC-1 cells that were cultured on fibronectin and were then
Tanouchi et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:190 Page 17 of 17labeled with anti-AMPK1 antibody (green), anti-CCDC88A antibody (red)
and phalloidin (violet; actin filaments). Arrows, AMPK1 localized in cell
protrusions. Blue, nuclear DAPI staining. Bar, 10 μm. (DOCX 631 kb)
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